Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Herpes Zoster (Shingles) - Overview Herpes Zoster (Shingles) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Herpes Zoster (Shingles) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development Beijing Minhai Biotechnology Co Ltd GeneOne Life Science Inc GlaxoSmithKline Plc NAL Pharmaceuticals Ltd NanoViricides Inc Vaccitech Ltd XBiotech Inc Herpes Zoster (Shingles) - Drug Profiles GLS-5100 - Drug Profile Product Description Mechanism Of Action R&D Progress herpes zoster vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress herpes zoster vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress herpes zoster vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies for Shingles - Drug Profile Product Description Mechanism Of Action R&D Progress NAL-3220 - Drug Profile Product Description Mechanism Of Action R&D Progress NN-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Shingles - Drug Profile Product Description Mechanism Of Action R&D Progress varicella zoster vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Herpes Zoster (Shingles) - Dormant Projects Herpes Zoster (Shingles) - Discontinued Products Herpes Zoster (Shingles) - Product Development Milestones Featured News & Press Releases Jan 26, 2018: GSK’s Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over Dec 06, 2017: Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates Dec 06, 2017: New data supports the safety and efficacy of GSK’s Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients Nov 20, 2017: New Shingles Vaccine: CUMC Experts Discuss what it Means for Patients Oct 26, 2017: Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center Oct 25, 2017: CDC’s Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up Oct 25, 2017: Shingrix with QS-21 Stimulon Receives Positive Recommendation from CDCs Advisory Committee on Immunization Practices as Preferred Vaccine for Prevention of Shingles Oct 23, 2017: Shingrix approved in the US for prevention of shingles in adults aged 50 and over Oct 20, 2017: FDA Approves GSK's Shingles Vaccine with Agenus QS-21 Stimulon Adjuvant Oct 13, 2017: GSK announces first approval of Shingrix in Canada Oct 13, 2017: GSK's Shingrix Containing Agenus' QS-21 Stimulon Adjuvant Receives Marketing Authorization from Health Canada Sep 13, 2017: FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over Sep 13, 2017: GSK's Shingrix Containing Agenus' QS-21 Stimulon Adjuvant Receives Unanimous FDA Advisory Committee Recommendation for Approval Jul 10, 2017: NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin Jun 26, 2017: NanoViricides Poster Novel Nanoviricides Highly Effective Against Varicella Zoster Virus in Cell Culture to be Presented Today at the 2017 Annual Meeting of American Society of Virology Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Herpes Zoster (Shingles), H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products by Stage and Target, H1 2018 Number of Products by Stage and Mechanism of Action, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018 Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H1 2018 Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H1 2018 Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H1 2018 Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H1 2018 Herpes Zoster (Shingles) - Pipeline by Vaccitech Ltd, H1 2018 Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H1 2018 Herpes Zoster (Shingles) - Dormant Projects, H1 2018 Herpes Zoster (Shingles) - Discontinued Products, H1 2018List of Figures Number of Products under Development for Herpes Zoster (Shingles), H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products by Stage and Targets, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018